Navigation Links
Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
Date:12/18/2007

CINCINNATI, Dec. 18 /PRNewswire/ -- Medpace, a leading global full-service contract research organization (CRO), is opening a 50 bed clinical pharmacology unit in Cincinnati, Ohio. The Medpace Clinical Pharmacology Unit (Medpace CPU) is a state-of-the-art Phase I, IIa facility, focusing on confined/controlled pharmacokinetic/pharmacodynamic studies utilizing human volunteers, with first-in-man capability.

The Medpace CPU is led by Jean Siebenaler, MD, who has extensive experience in clinical practice and CRO project management. The Medpace CPU will be managed by a team of highly trained, clinical research professionals, who are experts in the design, implementation, and analysis of Phase I and IIa studies. Jim Wei, MD, PhD, will be responsible for reviewing the early Phase studies of sponsors' products, recommending studies, and assisting with Phase I/Phase IIa study designs. Dr. Wei comes to Medpace from the FDA where he served as a Senior Reviewer in the Office of Clinical Pharmacology for almost 10 years where he was heavily involved in reviewing NDAs and INDs for the Divisions of Metabolism and Endocrinology Products.

Aligned with the Medpace approach of providing therapeutically focused clinical development services, the Medpace CPU will uniquely focus on studies in defined metabolic patient populations. The company's dedicated subject recruitment division, together with a strategic partnership with the renowned Metabolic and Atherosclerosis Research Center (MARC) led by Dr. Evan Stein, will facilitate efficient recruitment of populations which include: diabetics (Types I and II), patients with metabolic syndromes and cardiovascular diseases.

The secure, state-of-the-art, 24-hour, 7-day a week facility, features a thirteen bed intensive care/observation unit. The Medpace CPU is located across the street from the Medpace Reference Laboratories, a full service central lab which features therapeutically specialized testing. The site will have a full 12-Lead Mortara Telemetry system with wireless transmission to a centralized monitoring station which can monitor and record up to thirty-two patients simultaneously which allows for thorough QTc studies. The site also has the capacity for IV infusions, Holter monitoring, and pulmonary function testing.

Amenities for the study participants will include single beds, large flat screen TVs, video games, DVD players, desktop computers, wireless internet access, an enclosed outdoor courtyard, full-service catering, and a warming kitchen for in-house meal distribution.

The Medpace CPU is unprecedented in the region for its size and state-of- the-art equipment. Its presence continues to enhance the area's growing healthcare reputation and a commitment to pharmaceutical research.

"We are pleased to offer this state-of-the-art, highly specialized Phase I and IIa facility for our clients," said August Troendle, MD, Medpace Chief Executive Officer. "We believe our therapeutic expertise in cardiovascular, oncology, and metabolic clinical trials will be a unique offering in a market place that has a high demand for Phase I and II studies but rarely specializes in a few areas of focus."

Community volunteers interested in participation may call the unit directly and speak to a recruitment specialist at: (513) 366-3222 or (859) 341-9800.

About Medpace

Medpace is a global, research-based drug development company led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 550 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

The Medpace group of companies also includes:

Imagepace -- a core imaging laboratory

Medpace Reference Laboratories -- a centralized lab with therapeutically specialized testing
Medpace Clinical Pharmacology -- a Phase I/IIa unit

View the Medpace website at http://www.medpace.com.

Contact: John Wynne, 513-579-9911 x 2407

j.wynne@medpace.com


'/>"/>
SOURCE Medpace
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
4. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
5. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
6. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):